Biacore 3000 shared instrument

描述（由申请人提供）：Biacore 3000系统利用表面等离子体共振技术为生物分子结合的无标记研究提供自动化和灵敏的技术。可以研究从小分子到粗提物、脂质囊泡、病毒、细菌和真核细胞的样品。SPR技术的一般优点包括快速、灵敏、通用、使用的材料量少，并且是无标记的。目前唯一可用的仪器是bialite升级版，即使与常规BiacoreX相比，也在自动化、温度范围和灵敏度方面存在不足。用户有应用程序，将检查蛋白质-蛋白质，蛋白质-核酸和蛋白质药物相互作用。本申请的核心小组具有通过使用改良的BiacoreX（bialite升级）仪器使用该技术的经验，包括出版物。BiacoreX的局限性包括缺乏自动样品处理、灵敏度降低、温度使用范围有限以及仅使用传感器芯片上一半的流动池。此外，-3000专为单个样品表征而设计，在动力学分析中最高的分辨率是必不可少的，范围从4 RU到70000。升级到3000将克服所有这些限制，允许更大的灵活性，在实验设计和分析类型是可能的。该仪器将被放置在核酸研究核心设施中，由仪器的核心用户之一Greg Buck博士运行。已经确定了一名专门的操作员来运行样本并协助用户进行数据分析。这一设置将使核心用户和整个研究界都能更方便地使用该仪器。仪器操作和维护的支持将通过用户费用以及癌症中心和生命科学中心的大学支持来实现。

DESCRIPTION (provided by applicant): The Biacore 3000 system utilizes surface plasmon resonance technology to provide automated and sensitive technology for for label free studies of biomolecular binding. Samples ranging from small molecules to crude extracts, lipid vesicles, viruses, bacteria and eucaryotic cells can be studied. General advantages of SPR technology include being rapid, sensitive, versatile, small amount of material used, and is label-free. The only currently available instrument is a bialite upgrade that is deficient in automation, temperature range and sensitivity, even when compared to the regular BiacoreX. The users have applications which will examine protein-protein, protein-nucleic acid and protein drug interactions. The core group in this application has experience, including publications, using this technology via the use of the modified BiacoreX (bialite upgrade) instrument. The limitations of the BiacoreX include the lack of automatic sample handling, decreased sensitivity, limited temperature use range and use of only one-half of the flow cells on the sensor chip. In addition, the-3000 is designed for individual sample characterization where the highest resolution in kinetic analysis is essential and the range goes from as little as 4 RU to 70000. Upgrading to the 3000 will overcome all of these limitations, allowing much greater flexibility in experiment design and types of analyses that are possible. The instrument will be placed in the nucleic acids research core facility, run by Dr. Greg Buck, one of the core users of the instrument. A dedicated operator has been identified to run samples and assist users with data analysis. This set-up will allow much greater access to the instrument for both the core users as well as the research community as a whole. Support for the instrument operation and maintenance will be through user fees as well as university support from the cancer center and life sciences center.